Supplemental studies in progress propose that ARV-825 may also be effective in improving the response to estrogen deprivation (aromatase inhibition), another ingredient of standard of care in ER+ breast cancer. - "Our study unveiled the very important position of the KLF16/MYC regulatory axis in modulating tumor expansion and chemotherapy sensitivity https://abbv-744clinicaltrialphas25689.ja-blog.com/32079700/top-guidelines-of-abbv-744-safety-and-side-effects